Immuno-Oncology

Durvalumab received FDA priority review and breakthrough therapy designation for resectable gastric and GEJ adenocarcinoma.

Hossein Borghaei, DO, MS, discusses novel approaches to overcoming immunotherapy resistance in patients with non–small cell lung cancer.

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

Marina C. Garassino, MD, discusses the standing of durvalumab and other immunotherapy-based approaches in locally advanced NSCLC.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated findings for neoadjuvant nivolumab plus chemotherapy in resectable NSCLC.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss surgical outcomes from CheckMate-77T for perioperative nivolumab in resectable NSCLC.

Among patients with advanced melanoma and the target HLA type—representing 80% of the study population—treatment with iSCIB1+ yielded an ORR of 69%.

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated data from CheckMate-77T of perioperative nivolumab in resectable NSCLC.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy is affecting perioperative treatment in early-stage non–small cell lung cancer.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Bria-IMT plus checkpoint inhibition displayed a potential overall survival benefit in heavily pretreated, hormone receptor–positive breast cancer.

PD-L1 expression was more common in HRD-positive high-grade serous ovarian cancer, indicating potential prognostic value in newly diagnosed cases.

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

Nivolumab plus ipilimumab maintained an ORR benefit across subgroups of Chinese patients with unresectable hepatocellular carcinoma.

CheckMate 8HW data show ipilimumab plus nivolumab improved PFS vs nivolumab alone while maintaining HRQOL.

Durvalumab plus FLOT did not lead to differences in patient-reported outcomes vs placebo plus FLOT in resectable gastric/GEJ cancer.

Douglas B. Johnson, MD, MSCI, discusses clinical questions, unmet needs, and exciting therapeutic developments with immuno-oncology in melanoma.

Invikafusp alfa produced responses as a single agent in antigen-rich gastrointestinal tumors, including metastatic colorectal cancer.

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

Premal Thaker, MD, discusses findings for IMNN-001 plus perioperative chemotherapy in up-front, advanced ovarian cancer.

The combination of zelenectide pevedotin and pembrolizumab was safe and produced antitumor activity in cisplatin-ineligible urothelial cancer.

Douglas B. Johnson, MD, MSCI, discusses the importance of Cancer Immunotherapy Awareness Month and the utility of immunotherapy across tumor types.

Douglas B. Johnson, MD, MSCI, highlighted avenues for improving immunotherapy use in melanoma during Cancer Immunotherapy Awareness Month.